|
|
 |
|
Viewing report
|
|
|
|
The World Market For Sexual Disorders, 2005-2012: Traversing New Frontiers in Sexual Chemistry
Spectra Intelligence , Jan 2006, Pages: 124
The sexual disorder pharmacotherapy market is dominated by drugs indicated for erectile dysfunction which commands an estimated 78% of the total sexual disorder market valued at US$3 billion. Significant market opportunities are evident for the expansion of androgenic therapies to treat sexual disorders in new population groups such as in women with hypoactive sexual desire disorder and in male andropause. Furthermore, new drugs are on course to redefine the landscape of sexual medicine by offering novel therapies for premature ejaculation and specific desire-arousal disorders.
Emerging drug treatments targeting the unmet needs of women with sexual disorders are poised to revolutionize the market for sexual dysfunction, and Spectra predicts that the female sexual dysfunction sector may outperform those therapies indicated for male sexual disorders within a decade of availability. However, as a relatively young and controversial therapy area, new drugs for sexual disorders are subject to intense regulatory scrutiny and navigating through the drug approval process is challenging particularly for new sexual disorder indications, which is evident from recent market authorization setbacks for Proctor & Gamble's Intrinsa for female hypoactive sexual desire disorder and Johnson & Johnson/Alza's Dapoxetine for premature ejaculation. However, in this report, The World Market for Sexual Disorders, 2005-2012: Traversing New Frontiers in Sexual Medicine, the reader will be introduced to a specialty pharmaceutical market that is transitioning to a dynamic, high-value therapy area estimated to exceed US$6.6 billion by 2012.
The report provides a detailed analysis of the sexual disorders therapy area to include insights for product extension and reformulation, sales forecasts to 2012, and impact of late-stage pipeline drugs on the market. An overview of R&D programs within the field is also highlighted showing products from preclinical to premarket authorization phases of development, with promising agents further discussed from commercial and drug development perspectives. Therapy area forecasting and illustrative market data and analysis is also presented to offer insights into potential top-performing products. Therapy area forecasting to 2020 also enables the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling.
Objectives of the Report
The objectives of this report are to provide an in-depth analysis of the global sexual disorders therapy market. Included in this study are analyses of key therapy areas, R&D programs, and innovating companies and products. It is hoped that the reader will benefit from market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.
Research Methodology
The contents of this report are derived from in-depth research-based surveys of the industry; communication with senior corporate executives; and proprietary analytical assessment tools. Source material also comprises the following:
- Company information
- Personal communication
- Trade press articles
- News releases
- Internet-based research
- Library research
- Scientific periodicals
- Product information
- Market analyst data
- Public information datasets
- Conference proceedings
- Medical/pharma associations
WHAT CAN I LEARN FROM THIS REPORT?
- Which drugs are the current and potential future market leaders in the sexual dysfunction therapy domain
- Insights into utility of androgenic drugs to treat male andropause and female sexual disorders
- What impact new drug approvals will have on the sexual medicine drug market
- Which premarket drugs are identified as high-value products
- Which companies are developing drugs for male and female sexual disorders
- Sales predictions to 2012 for male sexual dysfunction therapies
- How will newcomers affect the product positioning of market leaders
- What are the niche market opportunities in sexual dysfunction
- What the future outlook may hold for sexual disorder pharmacotherapies
- How companies are expanding the global sexual medicine market through new indications and therapeutic switching
- Which molecules and compounds are main R&D clusters in sexual dysfunction drug development
- Which of the pipeline candidates are identified as top prospects over the next decade and to 2020
Plus Many Other Insights, Observations, Assumptions, and Predictions to be Garnered…
REPORT HIGHLIGHTS AND KEY FINDINGS
- The current market for drugs to treat sexual disorders is estimated at US$3.8 billion, which is forecast to increase 74% to US$6.6 billion by 2012
- Critical analysis of marketed sexual dysfunction drugs related to erectile dysfunction and androgen deficiency
- Analysis of over 20 key marketed and pipeline products and inclusion of 43 R&D candidates identified in preclinical to clinical stages of development
- Sales estimates (US$) to 2012 for leading products
- Strategic insights for life-cycle optimization and product development
- Commercial evaluation of leading sexual disorder pharmacotherapies
- Trend analysis of industry events and activities over past 2 years
- Detailed R&D themes and clusters by therapy area
- Data generation on sector and market values between 2004 and 2012 and therapy area forecasts by 2020 (US$)
- High revenue-yielding prospects identified with projected sales estimations
- R&D pipeline positioning for novel candidates
- Market insights for product development and drug promotion
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Female Sexual Dysfunction: Prescription Drug Pipeline Overview 2007
U.S. Sexual Dysfunction Medication Markets
Major Milestones: Female Sexual Dysfunction
Stakeholder Opinions: Female Sexual Dysfunction - Results From Datamonitors 2005 Physician Survey
Female Sexual Dysfunction Therapy Area Pipeline Report
Male and female sexual dysfunction: Blockbuster indication for multiple pharmacological targets
Strategic Perspectives: Female Sexual Dysfunction - Are Physicians and Patients Ready For a Female Viagra?
Handbook of Sexual and Gender Identity Disorders
Womens Health Female Sexual Dysfunction
Erectile Dysfunction Therapy Area Pipeline Report
Female Sexual Pain Disorders: Evaluation and Management
Stakeholder Opinion: Erectile Dysfunction - Identifying Product Differentiation and Patient Segmentation Strategies
|
|
|
|
